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Objective: To explore the expression, biological function and possible mechanism of
action of microRNA molecular-196a (miR-196a) in epithelial ovarian cancer.
Methods: RT-PCR was used to detect the expression quantities of epithelial ovarian tissue,
benign ovarian tissue, normal ovary epithelial tissue, ovarian cancer cell lines and miR-196a
in normal ovarian epithelial cells to analyze the relationship between the expression of miR-
196a and the clinical pathologic parameters of ovarian cancer.Among those cell lines, the cell
line of which miR-196a expressed the most or least was selected and transfected the ovarian
cancer cell line by using negative control plasma and miR-196a inhibitor. After transfection,
RT-PCR was used to test the expression quantity of miR-196a, Transwell chamber method
was applied to determine the migration and invasion abilities of ovarian carcinoma cells and
Western blot was employed to detect the expression of HOXA10 protein.
Results: The relative expression quantities of miR-196a in ovarian cancer tissue and benign
ovarian tissue were signiﬁcantly higher than that in normal ovarian epithelial tissue, and the
expression quantity ofmiR-196a in ovarian cancer tissuewas distinctively higher than that in
benign ovarian tissue (P< 0.05).Among 78 cases of epithelial ovarian cancer, the expression
quantities of miR-196a in patients with low differentiation were all signiﬁcantly higher than
those in patientswith high differentiation (P< 0.05). The expression ofmiR-196a showed no
signiﬁcant relationwith age, clinical stage andwhether CA125was positive or not in patients
(P > 0.05). Compared with normal ovarian epithelial cell line IOSE80, the expression
quantities of miR-196a of all ovarian cancer cell lines increased obviously and differences
were statistically signiﬁcant (P< 0.05). Among them, the expression ofmiR-196a of ovarian
cancer cell line SKOV3 was the highest, while it decreased signiﬁcantly (4.678 ± 0.785 vs.
2.131 ± 0.345, t = 2.938, P< 0.05) after the ovarian cancer cell line SKOV3was transfected
by miR-196a inhibitor. The results of Transwell chamber method showed that the migration
and invasion abilities of ovarian cancer cells SKOV3 were declined signiﬁcantly after the
expression of miR-196a was down-regulated and the difference showed statistical signiﬁ-
cance (P < 0.05). The results of Western blot revealed that the relative expression of
HOXA10 decreased distinctly after the expression of miR-196a was down-regulated and
also the difference showed statistical signiﬁcance (P < 0.05).
Conclusions: The miR-196a might serve as a cancer-promoting gene to promote the
migration and invasion of epithelial ovarian cancer by downstream target gene HOXA10.1. Introduction
The fatality rate of epithelial ovarian cancer has topped the
list of gynecologic malignant tumors. Epithelial ovarian canceris a common malignant tumor with concealed onset, difﬁcult for
early diagnosis, high rate of recurrence and migration, intrac-
table treatment and poor prognosis, which seriously threatens
women's life and health [1]. At present, researchers on the
pathogenesis of epithelial ovarian cancer are still in the stage
of exploration. Current studies mostly concentrate on levels of
gene regulation such as histone modiﬁcation, DNA
methylation and non-coding RNA [2–4]. Non-RNA is different
from protein-coding genes. It regulates and controls network to
regulate cell differentiation, disease occurrence and the nature of
biological evolution and heredity by new RNA-mediated genetic
massage expression, which provides new thoughts for theC BY-NC-ND license (http://
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eases with more and more attentions.
MicroRNA molecular-196a (miR-196a) is a member of the
non-code RNA family with a depth of 21–23 nucleotides, which
combines with downstream target gene mRNA 30 untranslated
regions (30-UTR) adequately or deﬁciently to speciﬁcally
explain or inhibit the translation of mRNA [5]. Many important
life activities such as the growth and differentiation of cells on
organisms are related to miRNA. It is supposed that miRNA
regulates and controls about 1/3 genes of all human genomes,
and it has been found that many diseases have relations with
the abnormal expression of miRNA [6–8]. Since half of the
miRNA are located in cancer-regulated-related chromosomal
domain fragile sites such as the regions of homozygous deletion,
loss of heterozygosity, oncogene and around tumor suppressor
gene, breakpoint area and ampliﬁed region, the occurrence and
development of tumors are closely related to miRNA. At the
moment, it has been proved that the expression or loss of
function of miRNA is closely associated with various tumors
such as breast cancer [9], liver cancer [10], non-small cell lung
cancer [11], gastric cancer [12], etc.
MiR-196a belongs to the family of homeotic genes (HOX)
and plays different roles in different cells and tissues. Re-
searches in recent years has found that the over-expression of
miR-196a in cervical cancer [13], oral cancer [14] and gastric
cancer [15] might play a role of cancer gene in regulating and
controlling the growth, differentiation and metastasis of
cancer cells. HOX is a kind of highly conserved homeobox
DNA sequence consisting of 39 transcription factors which
inﬂuence the growth and development of cells, embryos and
tissues according to anterior–posterior axis (A–P) in the
embryonic development period. It is found that the
over-expression of HOXA10, a family number of HOX, in
ovarian cancer is closely related to the occurrence of ovarian
cancer [16].
At present, although the expression and biological function
of miR-196a in ovarian cancer remain unknown, it is found
through bioinformatics ﬁnding aid that HOXA10 is one of the
downstream targets of miR-196a. Therefore, this study aimed to
discuss the expression and biological function of miR-196a in
epithelial ovarian cancer and to study whether miR-196a has a
role to play by regulating and controlling the target gene
HOXA10.
2. Materials and methods
2.1. Clinical tissue samples
A total of 78 epithelial ovarian cancer tissue samples ac-
quired from December 2013 to December 2015 in our hospital
were collected. Among them, 36 cases were benign ovarian
tissues and the other 36 were normal pathological sections of
ovary epithelial tissues. All samples were diagnosed deﬁnitely
by pathological method. Patients with epithelial ovarian cancer
received no radiotherapy, chemotherapy or immunotherapy
before operation. The ages of the 78 patients ranged from (29–
64) years with the average age of (47.75 ± 15.63) years. Out of
those patients, 33 cases were diagnosed with mucinous cys-
tadenocarcinoma and 45 suffered from serous papillary cys-
tadenocarcinoma. As for pathological grades, 43 cases were of
poorly differentiated stage and 35 were of highly to moderately
differentiated stage. Clinical stages consisted of 8 cases of Istage, 26 cases of II stage, 32 cases of III stage and 12 cases of
IV stage. The age of the 36 patients with benign ovarian tumors
ranged from 25 to 66 years with the average age of
(46.28 ± 16.28) years, and 16 cases of them were diagnosed with
mucinous cystadenoma and the other 20 cases were with
papillary cystadenoma. The other 36 cases of normal ovarian
epithelial tissues were all normal tissues collected from hyster-
ectomies with ages of (27–63) years and the average age of
(46.69 ± 16.10) years. The tissues were all quick-frozen by
placing them in liquid nitrogen once they were excised for
further application.
2.2. Cell culture
Ovarian cancer cell lines (SKOV3, OVCAR3, A2780, ES2)
and normal ovarian epithelial cells (IOSE80) were all purchased
from Shanghai Huiying Biological Technology co., Ltd. and
cultured in 10% fetal bovine serum medium with saturated hu-
midity and 5% CO2 at 37 C. Cells growing in the logarithmic
phase were selected and digested by 0.25% trypsin. The sub-
sequent experiments were conducted after 2–3 stable passages.
2.3. RT-PCR
About 150 mg of the pathological tissue samples were
selected, thawed, mixed, dissociated and centrifuged. RT-PCR
was used to test the expression quantity of miR-196a of each
pathological tissue sample and cell line. Firstly, TRIzol kits
(Invitrogen, USA) was applied to extract the total thyroid RNA.
The reverse transcription reaction system was set for RNA
reverse transcription to compound the ﬁrst-strand of modiﬁed
miRNA cDNA. PCR ampliﬁcation was conducted with the
ampliﬁcation system of RNU6B serving as the internal refer-
ence. The ampliﬁcation procedure were 50 C, 15 min, 95 C,
10 min, 95 C, 5 s, 60 C, 30 s which circulated for 40 times.
The recurring numbers reaching the cycle threshold value (Ct
value) in the tube were recorded. RNU6B correction was used
to acquire ▵Ct = CtmiR − 196a − CtRNU6B. 2−▵▵Ct method
was used to calculate the relative expression quantity of miR-
196a.
2.4. Plasma transfection
Negative control plasma (NC) and miR-196a inhibitor were
bought from Shanghai GenePharma Co., Ltd. The ovarian can-
cer cell line of which miR-196a expressed the most or least was
selected and inoculated in six-well plates of 2 × 106/well with
DMEM medium to culture until the cell conﬂuence exceeded
50%. According to the instructions of lipidosome Lip-
ofectamineTM200 (Promega, USA), ovarian cancer cell lines
growing in the logarithmic phase were transfected by NC and
miR-196a inhibitor plasmas respectively and cultured until the
ﬁnal volume reached 2 mL.
2.5. Transwell chamber method used to detect the
migration and invasion of ovarian carcinoma cells
RT-PCR was repeated to detect the changes of the expression
quantities of miR-196a in ovarian cancer cell lines after they
were transfected by miR-196a inhibitor plasmas. Transwell
chamber method was applied to determine the migration and
Table 1
Comparison of the relative expression quantities of miR-196a in various
tissues.
Tissues n ▵Ct value 2−▵▵Ct value
Ovarian cancer tissues 78 3.291 ± 0.364 5.308 ± 0.938*,#
Benign ovarian tissues 36 2.208 ± 0.271 3.624 ± 0.550*
Normal ovarian
epithelial tissues
36 1.089 ± 0.124 1.749 ± 0.265
*P < 0.05 compared with normal ovarian epithelial tissues; #P < 0.05
compared with benign ovarian tissues.
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Matrigel was added in serum-free DMEM culture solution for
liquefaction and dilution with 100 mL in each Transwell cham-
ber and then washed after peridium at 37 C. Two groups of
Transwell chambers were set. One was used for culturing
embedded peridium Matrigel (invasion experiment) and the
other did not have peridium Matrigel (migration experiment).
The upper culture embedded chamber of the Transwell chamber
was added with 2.5 × 104 cell suspension after transfected for
24 h and normal nutrient solution was added into in bottom at
the same time for 24 h. Paraformaldehyde was used for ﬁxing,
staining and washing after the lipid in the embedded chamber
was sucked out. After that, cell population was calculated with
the light microscope.
2.6. Western blot method used to detect the expression of
HOXA10 protein
The total protein was collected on ice and then denatural-
ized by boiling. BCA protein quantitative kits were used to
determine the content of protein and ELIASA was applied to
measure the absorbance at 562 nm. The protein concentration
was calculated according to the standard curve. Gel concen-
trations, separation gel and spacer gel were prepared in
accordance with the size of target protein. A proportion of 4:1
SDS-PAGE loading buffer was added for protein loading.
Spacer gel was used for electrophoresis. The set was closed by
defatted milk powder after transferring membrane with b-actin
serving as the internal reference. Primary antibodies were
added according to the dilution ratios ofb-actin (1:5 000) and
HOXA10 (1:1 000). Secondary antibodies (1:5 000) were
added after incubation at room temperature for 1 h and
washing. After 0.5 h of incubation at room temperature, they
were rinsed, colored, exposed and developing ﬁlms. Image J
software was employed to analyze the relative expression
quantity of the protein.
2.7. Statistical management
SPSS19.0 statistical software was used for statistical man-
agement. Measurement data were expressed by mean ± SD and
tested by t-test. Analysis of variance and repeated measurement
data were compared between groups. P < 0.05 showed statistical
signiﬁcance.3. Results
3.1. Comparison of the relative expression quantities of
miR-196a in various tissues
Results of ANOVA showed that differences of the compar-
ison of the relative expression quantities of miR-196a in ovarian
cancer tissues, benign ovarian tissues and normal ovarian
epithelial tissues were statistically signiﬁcant (P < 0.05). Further
pairwise comparison found that the relative expression quantities
of miR-196a in ovarian cancer tissues and benign ovarian tissues
were signiﬁcantly higher than that in normal ovarian epithelial
tissues, and the expression quantity of miR-196a in ovarian
cancer tissues was distinctly higher than that in benign ovarian
tissues (P < 0.05). The difference was statistically signiﬁcant
(P < 0.05) (Table 1).3.2. The correlation between the expression of miR-196a
in ovarian cancer tissues and clinical pathologic
parameters
In 78 cases of epithelial ovarian cancer, the expression
quantities of miR-196a in patients with low differentiation were
all signiﬁcantly higher than those in patients with high differ-
entiation. The difference was statistically signiﬁcant (P < 0.05).
The expression of miR-196a showed no signiﬁcant correlation
with the age and clinical stage of patients and also had no cor-
relation whether CA125 was positive or not in patients
(P > 0.05) (Table 2).
3.3. The expression quantities of miR-196a in normal
ovarian epithelial cell lines and ovarian cancer cell
lines
Compared with normal ovarian epithelial cell line IOSE80,
the expression quantity of miR-196a in each ovarian cancer cell
line increased signiﬁcantly and the differences were statistical
signiﬁcant (P < 0.05). Among them, the expression quantity of
miR-196a in ovarian epithelial cell line SKOV3 was the highest
(Table 3).
Expression quantity of miR-196a in each ovarian cancer cell
line was as follows, IOSE80 (normal ovarian surface epithelium)
was 1, SKOV3 was (4.678 ± 0.785), A2780 was
(4.092 ± 0.803), OVCAR3 was (3.278 ± 0.660), ES2 was
(2.863 ± 0.632).
3.4. Inﬂuence of down-regulation of miR-196a
expression in migration and invasion of ovarian
carcinoma cells SKOV3
The results of RT-PCR showed that the expression quantity
of miR-196a of ovarian cancer cell line SKOV3 decreased
signiﬁcantly (4.678 ± 0.785 vs. 2.131 ± 0.345, t = 2.938,
P < 0.05) after the ovarian cancer cell line SKOV3 was trans-
fected by miR-196a inhibitor. The results of Transwell chamber
method showed that the migration and invasion abilities of
ovarian cancer cells SKOV3 were declined signiﬁcantly after the
expression of miR-196a was down-regulated. Difference
showed statistical signiﬁcance (P < 0.05) (Table 3).
3.5. Inﬂuence of down-regulation of miR-196a
expression in HOXA10 protein in ovarian carcinoma
cells
After the ovarian cancer cell line SKOV3 was transfected by
miR-196a inhibitor to down-regulate the expression of miR-
Table 3
Inﬂuence of down-regulation of miR-196a expression in migration and
invasion of ovarian carcinoma cells SKOV3.
Group Migration number Invasion number
NC 81.60 ± 12.23 43.32 ± 5.19
MiR-196a inhibitor 32.24 ± 5.52 15.59 ± 4.33
t 15.536 10.293
P 0.000 0.000
Table 2
The correlation between the expression of miR-196a in ovarian cancer tissues and clinical pathologic parameters.
Clinical pathologic parameters n Relative expression quantity of miR-196a t P
Age S40 years 45 5.300 ± 0.927 0.382 0.893
<40 years 33 5.323 ± 0.930
Cell differentiation Low differentiation 43 6.164 ± 0.996 2.618 0.029
Medium-high differentiation 35 4.587 ± 0.928
Clinical stage I + II 34 5.276 ± 0.933 0.668 0.769
III + IV 44 5.463 ± 0.919
CA125 Positive 52 5.445 ± 0.952 0.569 0.811
Negative 26 5.256 ± 0.920
CA125  35 U/mL: Positive.
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HOXA10 protein. The results showed that the relative expres-
sion of HOXA10 decreased distinctly. Difference showed sta-
tistical signiﬁcance (P < 0.05). Relative expression of HOXA10
of Group NC and miR-196a inhibitor were (0.938 ± 0.124) and
(0.525 ± 0.083), respectively, with t = 2.920, P = 0.000.
4. Discussion
Epithelial ovarian cancer is a disease with concealed patho-
genesis and unconspicuous symptoms. Due to lack of effective
screening and early diagnosis method, most patients are at the
mid-late stage when they go to see their doctors. The death rate
of epithelial ovarian cancer maintains pretty high and is
extremely apt to reoccur and migrate with poor prognosis. The
survival rate is less than 30% in ﬁve years. At present, the
pathogenesis of epithelial ovarian cancer is not clear yet. It is
considered that understanding the molecular mechanism of the
occurrence and development of epithelial ovarian cancer cells
and unmasking the predictive molecular markers of differential
expression to search for biological markers with high sensitivity
for the early diagnosis of epithelial ovarian cancer will be
conductive to improving the diagnosis and treatment level of
epithelial ovarian cancer, which consequently promotes the
prognosis of the disease.
MiRNA is a class of small, single-stranded RNA molecules
which could not encode proteins. On one hand, miRNA can
combine with target gene 30-UTR adequately to speciﬁcally
degrade mRNA. On the other hand, miRNA inﬂuences the
translation of mRNA by combining with target gene 30-UTR
inadequately. By far, it is known that miRNA in various human
tumors expresses abnormally and loss functions [9–12]. However,
multiple miRNA express over or low in epithelial ovarian
cancer. For example, Li et al. [17] reported the low expression
of miR-217 in epithelial ovarian cancer tissues inhibits human
epithelial ovarian cancer cells by affecting target gene IGF1R,
which indicated that miR-217 could serve as a potential targetfor treating epithelial ovarian cancer. Ge and his colleagues
studied the possible effect of miR-215 in epithelial ovarian
cancer and found that the expression quantity of miR-215 in
epithelial ovarian cancer tissues and ovarian cancer cells
decreased signiﬁcantly, indicating that miR-215 might play an
anticancer role in the epithelial ovarian cancer. It was found that
the expression of XIAP was inhibited obviously after miR-215
was up-regulated. The decreased expression of XIAP can
inhibit the growth of ovarian cancer cells and promote apoptosis
and chemosensitivity. This study explored the relationship be-
tween the expression of miR-196a in epithelial ovarian cancer
and clinical pathological parameters. The results showed that the
relative expression quantities of miR-196a in ovarian cancer
tissue and benign ovarian tissue were signiﬁcantly higher than
that in normal ovarian epithelial tissue, and the expression
quantity of miR-196a in ovarian cancer tissue was distinctly
higher than that in benign ovarian tissue. Differences were sta-
tistically signiﬁcant (P < 0.05). In 78 cases of epithelial ovarian
cancer, the expression quantities of miR-196a in patients with
low differentiation were all signiﬁcantly higher than those in
patients with high differentiation. The difference was statisti-
cally signiﬁcant (P < 0.05). The results indicated that the
expression of miR-196a was related to cell differentiation. The
poorer the differentiation of cancer cells, the higher the
expression quantity of miR-196a will be. That further proved the
cancer gene function of miR-196a.
In the large among of biological characteristics, migration
and invasion are two important ones in cancer cells and also the
biological basis of distant migration of tumors [18,19]. Gene
transfection technique was employed in this study. The cancer
cell line SKOV3 with the highest expression quantity of miR-
196a was selected and transfected by miR-196a inhibitor. The
results showed that the expression quantity of miR-196a
declined distinctly after transfected by miR-196a inhibitor.
Transwell chamber method was further used to test the migration
and invasion abilities of ovarian cancer cells and found that the
migration and invasion abilities of ovarian cancer cells decrease
after down regulating the expression quantity of miR-196a.
Researches have found that miR-196a plays a role of cancer
gene in various cancers, but its relative signal mechanism has
differences [20–27]. In head and neck tumors, miR-196a exert its
biological functions by targeting HOXB9 [20]. Huang and his
colleagues [21] investigated the effect of miR-196a in pancreas.
They discovered the high expression of miR-196a in pancreas
and found that the expression of NFKBIA protein could be
increased by down regulating the expression of miR-196a, while
silencing NFKBIA protein expression could improve the
migration and proliferation of pancreatic cancer cells. Zhang
et al. [22] discovered that miR-196a adjusts the migration and
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netrin-4. Previous studies revealed that the over expression of
HOXA10, a family member of HOX, was closely related to the
occurrence of ovarian cancer [28–30]. It is found through
bioinformatics ﬁnding aid that 30-UTR HOXA10 mRNA
possessed a speciﬁc binding sequence of miR-196a and it is
one of the downstream targets of miR-196a. For that reason,
Western blot method was further used to detect the expression of
HOXA10 protein in this study and the results showed that the
relative expression quantity of HOXA10 decreased signiﬁcantly
after down regulating the expression of miR-196a. Differences
were statistically signiﬁcant. The results illustrated that miR-
196a may serve as a cancer-promoting gene that promotes the
migration and invasion of epithelial ovarian cancer by down-
stream target gene HOXA10.
In conclusion, the increased expression quantity of miR-196a
in epithelial ovarian cancer tissues was observed. The expression
quantity of miR-196a was concerned with the cell differentiation
degree. After the ovarian cancer cells were transfected by miR-
196a inhibitor, the expression quantity of ovarian cancer cells
declined evidently, the migration and invasion abilities
decreased signiﬁcantly and also the expression of HOXA10
protein was down-regulated. The effect of miR-196a in the
occurrence and development of epithelial ovarian cancer and its
possible regulatory pathway are preliminarily clear, which pro-
vides new clues for further researches on molecular mechanism.
However, due to the small sample size of this study, the re-
lationships between miR-196a and target gene HOXA10 and
between the miR-196a and its expression regulation and the
occurrence and development of epithelial ovarian cancer still
require further deep-going researches.Conﬂict of interest statement
We declare that we have no conﬂict of interest.
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